Analysing triggers for anti-NMDA-receptor encephalitis including herpes simplex virus encephalitis and ovarian teratoma: results from the Queensland Autoimmune Encephalitis cohort.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
11 2022
Historique:
revised: 26 05 2021
received: 10 03 2021
accepted: 28 05 2021
pubmed: 3 8 2021
medline: 23 11 2022
entrez: 2 8 2021
Statut: ppublish

Résumé

Anti-N-methyl-D-aspartate-receptor (anti-NMDA-R) encephalitis is a complex autoimmune neuropsychiatric syndrome. Although initially associated with ovarian teratoma, subsequent studies have demonstrated that anti-NMDA-R encephalitis may occur without an identifiable cause or be triggered by viral infection of the central nervous system such as herpes simplex virus encephalitis (HSVE). To present details from a Queensland cohort analysing triggering events in patients with anti-NMDA-R encephalitis in an Australian context. The authors identified patients with anti-NMDA-R encephalitis diagnosed and managed through public hospitals in Queensland, Australia, between 2010 and the end of 2019. Data collected included demographics, clinical presentation, investigation results, management and outcome measurements. Thirty-one cases of anti-NMDA-R encephalitis were included in the study. Three cases of anti-NMDA-R encephalitis were triggered by prior HSVE, five cases were associated with ovarian teratoma and 23 cases had no identifiable trigger. There were an additional three cases in which anti-NMDA receptor antibodies were present in the context of other disease states but where the patient did not develop anti-NMDA-R encephalitis. Cases triggered by HSVE or associated with ovarian teratoma experienced a more severe disease course compared to cases with no identifiable trigger. All groups responded to immunosuppressive or immunomodulatory therapy. Analysis of clinical characteristics revealed a complex heterogeneous syndrome with some variability between groups. In this cohort, the number of cases of anti-NMDA-R encephalitis triggered by HSVE is comparable to those triggered by ovarian teratoma. However, the majority of cases of anti-NMDA-R encephalitis had no identifiable trigger or associated disease process.

Sections du résumé

BACKGROUND
Anti-N-methyl-D-aspartate-receptor (anti-NMDA-R) encephalitis is a complex autoimmune neuropsychiatric syndrome. Although initially associated with ovarian teratoma, subsequent studies have demonstrated that anti-NMDA-R encephalitis may occur without an identifiable cause or be triggered by viral infection of the central nervous system such as herpes simplex virus encephalitis (HSVE).
AIM
To present details from a Queensland cohort analysing triggering events in patients with anti-NMDA-R encephalitis in an Australian context.
METHODOLOGY
The authors identified patients with anti-NMDA-R encephalitis diagnosed and managed through public hospitals in Queensland, Australia, between 2010 and the end of 2019. Data collected included demographics, clinical presentation, investigation results, management and outcome measurements.
RESULTS
Thirty-one cases of anti-NMDA-R encephalitis were included in the study. Three cases of anti-NMDA-R encephalitis were triggered by prior HSVE, five cases were associated with ovarian teratoma and 23 cases had no identifiable trigger. There were an additional three cases in which anti-NMDA receptor antibodies were present in the context of other disease states but where the patient did not develop anti-NMDA-R encephalitis. Cases triggered by HSVE or associated with ovarian teratoma experienced a more severe disease course compared to cases with no identifiable trigger. All groups responded to immunosuppressive or immunomodulatory therapy. Analysis of clinical characteristics revealed a complex heterogeneous syndrome with some variability between groups.
CONCLUSION
In this cohort, the number of cases of anti-NMDA-R encephalitis triggered by HSVE is comparable to those triggered by ovarian teratoma. However, the majority of cases of anti-NMDA-R encephalitis had no identifiable trigger or associated disease process.

Identifiants

pubmed: 34339078
doi: 10.1111/imj.15472
doi:

Substances chimiques

Receptors, N-Methyl-D-Aspartate 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1943-1949

Subventions

Organisme : Health Innovation, Investment and Research Office, Junior Doctor Fellowship
Organisme : Mater Foundation, Betty McGrath Fellowship

Informations de copyright

© 2021 Royal Australasian College of Physicians.

Références

Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36.
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-8.
Dalmau J, Armangue T, Planaguma J, Radosevic M, Mannara F, Leypoldt F et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol 2019; 18: 1045-57.
Armangue T, Leypoldt F, Málaga I, Raspall-Chaure M, Marti I, Nichter C et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014; 75: 317-23.
Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018; 17: 760-72.
Schäbitz GW-R, Rogalewski GA, Hagemeister GC, Bien GC. VZV brainstem encephalitis triggers NMDA receptor immunoreaction. Neurology 2014; 83: 2309-11.
Sakiyama Y, Matsuura E, Shigehisa A, Hamada Y, Dozono M, Nozuma S et al. Cryptococcus meningitis can co-occur with anti-NMDA receptor encephalitis. Internal medicine (Tokyo, Japan) 2020; 59: 2301-6.
Moloney PB, Hutchinson S, Heskin J, Mulcahy F, Langan Y, Conlon NP et al. Possible N-methyl-D-aspartate receptor antibody-mediated encephalitis in the setting of HIV cerebrospinal fluid escape. J Neurol 2020; 267: 1348-52.
Titulaer MJ, Höftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 75: 411-28.
Bartels F, Strönisch T, Farmer K, Rentzsch K, Kiecker F, Finke C. Neuronal autoantibodies associated with cognitive impairment in melanoma patients. Ann Oncol 2019; 30: 823-9.
Cohen KJ, Sotoca GJ, Gandhi DS, Yeshokumar CA, Gordon-Lipkin CE, Geocadin CR et al. Autoimmune encephalitis: a costly condition. Neurology 2019; 92: e964-72.
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-65.
Deng S, Qiu K, Liu H, Wu X, Lei Q, Lu W. Clinical characteristics and short-term prognosis of autoimmune encephalitis: a single-center cohort study in Changsha, China. Front Neurol 2019; 10: 539.
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-7.
Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol 2019; 18: 1045-57.

Auteurs

Andrew Swayne (A)

Mater Hospital, Mater Centre for Neurosciences, Brisbane, Queensland, Australia.
The University of Queensland, School of Medicine, Brisbane, Queensland, Australia.
Department of Neurology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Nicola Warren (N)

The University of Queensland, School of Medicine, Brisbane, Queensland, Australia.
Department of Psychiatry, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Kerri Prain (K)

HSQ Pathology Queensland Central Laboratory, Division of Immunology, Royal Brisbane and Women's Hospital Campus, Brisbane, Queensland, Australia.

David Gillis (D)

HSQ Pathology Queensland Central Laboratory, Division of Immunology, Royal Brisbane and Women's Hospital Campus, Brisbane, Queensland, Australia.

Richard Wong (R)

HSQ Pathology Queensland Central Laboratory, Division of Immunology, Royal Brisbane and Women's Hospital Campus, Brisbane, Queensland, Australia.
Department of Immunology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Stefan Blum (S)

Mater Hospital, Mater Centre for Neurosciences, Brisbane, Queensland, Australia.
The University of Queensland, School of Medicine, Brisbane, Queensland, Australia.
Department of Neurology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH